Mycophenolate mofetil for systemic vasculitis and IgA nephropathy

Lancet

Volumn 349, Issue 9054, 1997, Pages 774-

  Nowack, Rainer ^b   Birck, Rainer ^b   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ARTICLE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC VASCULITIS;

EID: 0343472033     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60198-5     Document Type: Article

References (5)

1. van der Woude FJ. Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dial Transplant 1995; 10: 1112-15.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-25.
3. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
4. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
5. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377-87.